Core Viewpoint - MIRXES-B, a Singapore-based microRNA technology company, has seen its stock price rise significantly since its IPO, reflecting strong market interest and potential growth opportunities in the molecular diagnostics sector [1] Company Summary - MIRXES-B's stock price reached a new high of 47.8 HKD, marking an 8.1% increase during trading, with a market capitalization of approximately 13.2 billion HKD [1] - Since its listing on May 23, the stock has appreciated by 105% from its initial offering price of 23.3 HKD [1] Industry Summary - The company has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO, a company listed on the Indonesian stock exchange, to collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of cancers with high incidence and mortality rates in Indonesia [1] - The memorandum is set for a duration of 12 months, indicating a strategic move to expand into emerging markets with high growth potential [1]
港股异动丨MIRXES-B涨8%续创上市新高 上市迄今不到3个月股价已翻倍！